Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Profluent announced a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address…
Kilobase-scale DNA editing remains a holy grail in genetic medicine. Our work with Lilly is aimed at unlocking these therapeutics previously thought…
Eli Lilly has strengthened its position in the rapidly evolving field of AI-driven biotechnology by entering a major partnership with startup Profluent. The US…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Lilly signed a multi-program collaboration with Bezos-backed Profluent to co-develop AI-designed site-specific recombinases for genetic medicines; Profluent eligible for an undisclosed upfront, R&D funding, and up to $2.25B in development/commercial milestones plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Profluent Bio (this deal) | 2026 | $2.2B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Rare Disease deals